Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Single-center, Open-label, Randomized, Comparator-controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis Known or Suspected to be Due to Gram-Positive Organisms

NCT02685033 is registered in ClinicalTrials.gov with Durata Therapeutics Inc., an affiliate of Allergan plc as lead sponsor.

NCT NCT02685033
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02685033 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Single-center, Open-label, Randomized, Comparator-controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis Known or Suspected to be Due to Gram-Positive Organisms
Lead sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Phase
Phase 2
Overall status
Completed
Start date
March 15, 2016
Completion date
December 12, 2017
Enrollment
80 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

osteomyelitis